Improving Survival in Idiopathic Pulmonary Fibrosis The Race Has Just Begun

被引：8
作者：
Collard, Harold R. [1 ]
机构：
[1] Univ Calif San Francisco, Dept Med, 505 Parnassus Ave,Campus Box 0111, San Francisco, CA 94143 USA
来源：
CHEST | 2017年 / 151卷 / 03期
关键词：
NETWORK METAANALYSIS; CLINICAL-TRIALS; PHASE-2; TRIAL; DOUBLE-BLIND; END-POINT; PIRFENIDONE; NINTEDANIB; MORTALITY; EFFICACY; PLACEBO;
D O I：
10.1016/j.chest.2017.01.007
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：527 / 528
页数：2
相关论文
共 15 条
[1]  
[Anonymous], 2015, BMC PULM MED, DOI [10.1186/s12890-015-0034-y, DOI 10.1186/S12890-015-0034-Y]
[2]   Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis [J].
Aravena, Carlos ;
Labarca, Gonzalo ;
Venegas, Carmen ;
Arenas, Alex ;
Rada, Gabriel .
PLOS ONE, 2015, 10 (08)
[3]   Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial [J].
Behr, Juergen ;
Bendstrup, Elisabeth ;
Crestani, Bruno ;
Guenther, Andreas ;
Olschewski, Horst ;
Skoeld, C. Magnus ;
Wells, Athol ;
Wuyts, Wim ;
Koschel, Dirk ;
Kreuter, Michael ;
Wallaert, Benoit ;
Lin, Chin-Yu ;
Beck, Juergen ;
Albera, Carlo .
LANCET RESPIRATORY MEDICINE, 2016, 4 (06) :445-453
[4]   Drug Treatment of Idiopathic Pulmonary Fibrosis Systematic Review and Network Meta-Analysis [J].
Canestaro, William J. ;
Forrester, Sara H. ;
Raghu, Ganesh ;
Ho, Lawrence ;
Devine, Beth E. .
CHEST, 2016, 149 (03) :756-766
[5]   A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials [J].
Collard, Harold R. ;
Bradford, Williamson Z. ;
Cottin, Vincent ;
Flaherty, Kevin R. ;
King, Talmadge E., Jr. ;
Koch, Gary G. ;
Kolb, Martin ;
Martinez, Fernando J. ;
Montgomery, Bruce ;
Raghu, Ganesh ;
Richeldi, Luca ;
Rose, Dan ;
Wells, Athol U. ;
Brown, Kevin K. .
EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (01) :243-249
[6]   Idiopathic Pulmonary Fibrosis Lung Function Is a Clinically Meaningful Endpoint for Phase III Trials [J].
du Bois, Roland M. ;
Nathan, Steven D. ;
Richeldi, Luca ;
Schwarz, Marvin I. ;
Nobles, Paul W. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (08) :712-715
[7]   Forced Vital Capacity in Idiopathic Pulmonary Fibrosis - FDA Review of Pirfenidone and Nintedanib [J].
Karimi-Shah, Banu A. ;
Chowdhury, Badrul A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (13) :1189-1191
[8]   A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis [J].
King, Talmadge E., Jr. ;
Bradford, Williamson Z. ;
Castro-Bernardini, Socorro ;
Fagan, Elizabeth A. ;
Glaspole, Ian ;
Glassberg, Marilyn K. ;
Gorina, Eduard ;
Hopkins, Peter M. ;
Kardatzke, David ;
Lancaster, Lisa ;
Lederer, David J. ;
Nathan, Steven D. ;
Pereira, Carlos A. ;
Sahn, Steven A. ;
Sussman, Robert ;
Swigris, Jeffrey J. ;
Noble, Paul W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) :2083-2092
[9]   Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis [J].
Nathan, Steven D. ;
Albera, Carlo ;
Bradford, Williamson Z. ;
Costabel, Ulrich ;
Glaspole, Ian ;
Glassberg, Marilyn K. ;
Kardatzke, David R. ;
Daigl, Monica ;
Kirchgaessler, Klaus-Uwe ;
Lancaster, Lisa H. ;
Lederer, David J. ;
Pereira, Carlos A. ;
Swigris, Jeffrey J. ;
Valeyre, Dominique ;
Noble, Paul W. .
LANCET RESPIRATORY MEDICINE, 2017, 5 (01) :33-41
[10]   Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial [J].
Raghu, Ganesh ;
Brown, Kevin K. ;
Collard, Harold R. ;
Cottin, Vincent ;
Gibson, Kevin F. ;
Kaner, Robert J. ;
Lederer, David J. ;
Martinez, Fernando J. ;
Noble, Paul W. ;
Song, Jin Woo ;
Wells, Athol U. ;
Whelan, Timothy P. M. ;
Wuyts, Wim ;
Moreau, Emmanuel ;
Patterson, Scott D. ;
Smith, Victoria ;
Bayly, Selina ;
Chien, Jason W. ;
Gong, Qi ;
Zhang, Jenny J. ;
O'Riordan, Thomas G. .
LANCET RESPIRATORY MEDICINE, 2017, 5 (01) :22-32
12